Sana Biotechnology Inc (SANA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sana Biotechnology Inc (SANA) has a cash flow conversion efficiency ratio of -0.313x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.38 Million) by net assets ($119.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sana Biotechnology Inc net asset quality index to measure how much of total assets are equity-financed.
Sana Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Sana Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SANA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Sana Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sana Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sudarshan Chemical Industries Limited
NSE:SUDARSCHEM
|
-0.036x |
|
CureVac NV
F:5CV
|
0.034x |
|
AA Industrial Belting
SHG:603580
|
0.009x |
|
Welspun Enterprises Limited
NSE:WELENT
|
-0.147x |
|
Crystal Growth & Energy Equipment Co. Ltd. A
SHG:688478
|
N/A |
|
Regional Container Lines Public Company Limited
BK:RCL
|
0.054x |
|
Cementos Pacasmayo SAA ADR
NYSE:CPAC
|
0.032x |
|
CNB Financial Corporation
NASDAQ:CCNE
|
0.008x |
Annual Cash Flow Conversion Efficiency for Sana Biotechnology Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Sana Biotechnology Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see SANA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $160.88 Million | $-143.83 Million | -0.894x | -0.36% |
| 2024-12-31 | $250.50 Million | $-223.15 Million | -0.891x | -1.00% |
| 2023-12-31 | $287.51 Million | $-253.58 Million | -0.882x | -51.84% |
| 2022-12-31 | $499.31 Million | $-290.05 Million | -0.581x | -68.56% |
| 2021-12-31 | $728.50 Million | $-251.05 Million | -0.345x | -205.19% |
| 2020-12-31 | $-421.18 Million | $-137.98 Million | 0.328x | -45.39% |
| 2019-12-31 | $-142.54 Million | $-85.50 Million | 0.600x | -41.38% |
| 2018-12-31 | $-13.19 Million | $-13.49 Million | 1.023x | -- |
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more